← Eichor
Study identifier: NCT05757687 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Evaluation of the Safety, Tolerability, and Efficacy of the Omega System for the Treatment of LUTS Due to BPH

Condition: Lower Urinary Tract Symptoms · Benign Prostatic Hyperplasia  ·  Sponsor: ProArc Medical

PhaseNA
Planned participants11
Who can joinMale, 50 Years to no upper limit
Healthy volunteersNo

About this study

This is a prospective, two-stage, multi-center, pilot clinical study to evaluate the safety/tolerability/efficacy of the Omega System device. The Omega arc-shaped implant is inserted by the Omega delivery system into the prostate tissue of subjects to relieve lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). The study will first evaluate the Omega system on patients undergoing prostatectomy, which is not indicated for the device.

This description comes directly from the study's public registry record.

Talk to the study team

Fay Dan  ·  972-544-781-599  ·  fay@proarcmedical.com

Always discuss trial participation with your own doctor first.

Locations (5)

N(N)LE New Vision University HospitalTbilisi, GeorgiaRecruiting
Israeli-Georgian Medical Research Clinic HealthycoreTbilisi, GeorgiaRecruiting
JSC L.Managadze National Center of UrologyTbilisi, GeorgiaRecruiting
Tbilisi Heart CenterTbilisi, GeorgiaRecruiting
Todua ClinicTbilisi, GeorgiaTerminated

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05757687